ALSO NOTED: Government could force doc disclosures; Barr sues Watson over Seasonique patent;

> The government is considering requiring pharma companies to disclose their doc-consulting deals as part of any settlement agreements. Report [1] | Report [2]

> Duramed, a Barr Pharmaceuticals subsidiary, filed a patent infringement suit against Watson Pharmaceuticals, alleging it had infringed on its patent for the contraceptive Seasonique. Release [3]

> Teva sued the FDA for denying its exclusivity period for its version of the antipsychotic Risperdal, which goes off patent this year. Release [4]

> Genzyme launched its phosphate-binding drug Renvela for use in dialysis patients in the U.S. Release [5]

> Baxter may test its immune booster Gammagard against Alzheimer's after a medical claims analysis indicated the risk of developing the disease could be reduced in patients previously treated with the med. Report [6]

> A new study showed that Novartis' cancer drug Gleevec could harm fetal development if the child was conceived during treatment. Report [7]

> With no "firm" buyout offers coming in, PDL BioPharma has decided to axe 260 workers--on top of the 320 layoffs already announced--and take itself off the market. Report [8]

> After concluding that its late-stage trial of MC-1 failed to hit its primary endpoint, Medicure has announced plans to slash 50 workers and full-time consultants. Report [9]

> The FDA is sending signals that it will start to let deadlines for drug approvals go by the wayside. Report [10]

And Finally... Surgery may effectively cure Type II diabetes, according to a new study in Diabetes Care. Report [11]